Skip to content

Analysis of adverse reactions of antitumor drugs in elderly patients with lung cancer and construction of evaluation model

Analysis of adverse reactions of antitumor drugs in elderly patients with lung cancer and construction of evaluation model

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093695
Enrollment
Unknown
Registered
2024-12-10
Start date
2024-12-11
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Old group(65 years old and above):None
Young and middle-aged (less than 65 years old) group:None

Sponsors

Quzhou People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Diagnosed as lung cancer through pathological examination and admitted to the hospital for chemotherapy, immunotherapy, or chemotherapy combined with immunotherapy; 2.TNM staging: Stage IIIB or Stage IV; 3.Expected survival time>6 months.

Exclusion criteria

Exclusion criteria: 1.Suffering from mental illness or consciousness disorders; 2.Suffering from serious illnesses in other organs or systems such as the heart, brain, blood vessels, liver and kidney; 3.Suffering from severe visual and auditory impairments; 4.Low compliance or unwillingness to participate in this study. 5.The subject has a history of drug abuse (defined as the use of any prohibited drugs) or alcohol abuse.

Design outcomes

Primary

MeasureTime frame
Clinical treatment efficacy and adverse reaction characteristics of elderly and young and middle-aged patients;Metabolite levels;Differences in the expression of key genes in the enzymatic process of drug biotransformation;

Countries

China

Contacts

Public ContactGeriletu Ao

Quzhou People's Hospital

ge_ao@wmu.edu.cn+86 139 4854 3938

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026